Novel treatments for melanoma over the past decade have dramatically enhanced survival. Immune checkpoint inhibitors and BRAF/MEK inhibitors have both demonstrated significant improvements in melanoma patient outcomes as demonstrated by many clinical trials. Unfortunately, patients who develop brain metastases still carry a grim prognosis, with a median overall survival of fewer than 6 months. Additionally, there is relatively […]